Why Harrow, Inc.’s (HROW) Stock Is Down 5.82%
As of Friday, October 09, Harrow, Inc.’s HROW share price has dipped by 5.82%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Commentary & Analysis
Why Harrow, Inc.’s (HROW) Stock Is Down 8.29%
As of Monday, September 28, Harrow, Inc.’s HROW share price has dipped by 8.29%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Harrow, Inc.’s (HROW) Stock Is Up 5.50%
As of Wednesday, August 19, Harrow, Inc.’s HROW share price has surged by 5.50%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Harrow, Inc.’s (HROW) Stock Is Down 5.40%
As of Friday, July 24, Harrow, Inc.’s HROW share price has dipped by 5.40%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Harrow, Inc.’s (HROW) Stock Is Up 5.27%
As of Wednesday, June 17, Harrow, Inc.’s HROW share price has surged by 5.27%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | HROW | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,021.2 | $476.9 | 46% |
|
| Shares Out (Mil) | 37.4 | 42.8 | 41% |
|
| Institutional Ownership | 76.1% | 81.8% | 46% |
|
| Float (Mil) | 28.9 | 44.5 | 35% |
|
| Beta | 0.24 | 0.71 | 14% |
|
| Avg Daily Volume (000s) | 684 | 362 | 63% |
|
| Price Change (52-week) |
(29.7%) | 54.5% | 30% |
|
| Growth | HROW | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 41.0% | 6.1% | 94% |
|
| Net Income (5yr) | (8.4%) | (2.0%) | 31% |
|
| EPS (5yr) | (1.5%) | 15.0% | 29 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 90.9% | (15.1%) | 98% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 3 | 4 | |
| Current EPS | $0.320 | $0.433 | $2.773 | |
| Month Ago EPS | $0.320 | $0.450 | $2.833 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.377 | $0.447 | $2.677 | |
| Year/Year Chg | (169.3%) | (409.3%) | (3,164%) | |
| Financials | HROW | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $276 | $416 | 35% |
|
| Net Income (TTM) (Mil) | ($37) | ($11) | 19% |
|
| EPS (TTM) | ($0.999) | ($0.700) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | $6 | ($7) | 37% |
|
| Net Cash Flow (TTM) (Mil) | $31 | $5 | 66% |
|
| Long-Term Debt (Q1) (Mil) | $300 | $6 | 53% |
|
| Enterprise Value (Q1) (Mil) | $1,455 | $494 | 45% |
|
| Valuation | HROW | Industry Median |
Percentile (All Stocks) |
|
| P/B | 66.44 | 2.17 | 99% |
|
| P/E | na | 17.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | HROW | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 73.3% | 69.4% | 84% |
|
| Net Margin | (13.5%) | 3.2% | 19% |
|
| ROA | (9.8%) | (22.2%) | 26% |
|
| ROE | (114.8%) | (21.4%) | 8% |
|
| Liabilities to Assets | 96.4% | 32.8% | 93% |
|
| F-Score | 4 | 3 | 33% |
|
Harrow, Inc. did not pass any screens on 10/14/2026.
